ArticleDiabetology & metabolic syndrome2025

Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.

Junling Weng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.